RT Journal Article
SR Electronic
T1 THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20115238
DO 10.1101/2020.05.27.20115238
A1 Binh T. Ngo
A1 Paul Marik
A1 Pierre Kory
A1 Leland Shapiro
A1 Raphael Thomadsen
A1 Jose Iglesias
A1 Stephen Ditmore
A1 Marc Rendell
A1 Daniel Griffin
A1 Joseph Varon
A1 Michael Dubé
A1 Neha Nanda
A1 Gino In
A1 Daniel Arkfeld
A1 Preet Chaudhary
A1 Vito M. Campese
A1 Diana L. Hanna
A1 David E. Sawcer
A1 Glenn Ehresmann
A1 David Peng
A1 Miroslaw Smogorewski
A1 April Armstrong
A1 Rajkumar Dasgupta
A1 Fred Sattler
A1 Cristina Mussini
A1 Oriol Mitja
A1 Vicente Soriano
A1 Nicolas Peschanski
A1 Gilles Hayem
A1 Marco Confalonieri
A1 Maria Carmela Piccirillo
A1 Antonio Lobo-Ferreira
A1 Iraldo Bello Rivero
A1 Cuba Havana
A1 Eivind H. Vinjevoll
A1 Ivan FN Hung
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.05.27.20115238.abstract
AB BACKGROUND The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World, with a total of 29,155,581 confirmed cases of COVID-19, including 926,544 deaths worldwide as of September 15, 2020. Projections are for continued new infections and deaths if no effective therapeutic interventions can be initiated over the next several months. We performed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and continuing in the last half of 2020.Clinical Trials We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed as of September 1, 2020 on identified agents We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly observational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects, since smaller trial size could lack statistical power to establish superiority of the intervention over the control.Publications We searched for published trial results on pubmed.gov and on medRxiv, the preprint server, and used a targeted Google™ search to find announcements of unpublished trial resultsClinical Trials in Recruitment As of our cutoff date of April 1, 2020, we found 409 trials meeting our minimum requirement of 100 subjects. The WHO Solidarity megatrial for hospitalized patients was launched in over 100 countries, actively comparing hydroxychloroquine (HCQ), lopanovir/ritonavir (LPV/r) alone and in combination with interferon beta-1, and remdesivir. The LPV/r alone and HCQ arms have already been discontinued. Of these, only 9 were conducted on outpatients. A few vaccine trials are hoping to complete Phase 3 enrollment by the end of the third quarter 2020, but a prolonged follow-up of patients will likely be required.Clinical trials Completed As of September 1, 2020, there were 231 trials reporting completion, Of these, only 59 studies enrolled 100 or more subjects. There were 34 trials in hospitalized patients, 9 directed at outpatients, and 8 prevention studies,Published Data As of September 1, 2020 we found 70 publications reporting findings in human studies on 13 classes of drugs and on 6 vaccines. There were 33 randomized placebo or active control studies; the rest were retrospective observational. Only seven publications dealt with outpatient care, the rest all in hospitalized patients.Available Treatments At this time, remdesivir and convalescent plasma have been granted emergency use authorization in the U.S.A., solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. No treatments or prophylaxis are offered for outpatients.CONCLUSION COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few randomized, controlled outpatient studies expected to yield results in time to impact on the continuing pandemic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World’s population.Competing Interest StatementDr. Armstrong reports grants and personal fees from Abbvie, grants and personal fees from Bristol-Myers Squibb, personal fees from Dermavant, grants from Dermira, grants and personal fees from Eli Lilly, grants and personal fees from Janssen, grants from Kyowa Hakko Kirin, grants and personal fees from LEO Pharma, grants and personal fees from Modernizing Medicine, grants and personal fees from Novartis, personal fees from Ortho-Dermatologics, personal fees from Pfizer, grants and personal fees from Regeneron, personal fees from Sanofi-Genzyme, personal fees from Science 37, Inc, grants from UCB Biopharma Dr. Dube reports grants from Gilead Sciences, outside the submitted work; Dr. Chaudhary has held stock in Gilead Sciences, Roche Holding and Moderna. Dr. Piccirillo reports personal fees from Daichii Sankyo, personal fees from GSK, personal fees from MSD, grants from Roche, grants and personal fees from AstraZeneca, non-financial support from Bayer, outside the submitted work; . Dr. Mussini is member of a Roche Data Safety Monitoring Board for tocilizumab Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB needed for systematic analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have provided a comprehensive list of all clinical trials with their registration as Supplementary Table 1 https://www.covid-trials.org/ https://clinicaltrials.gov/ https://www.who.int/ictrp/en/ https://reaganudall.org/covid-19